Revista espanola de cardiologia最新文献

{"title":"Reparación de borde a borde de la válvula tricúspide y hospitalizaciones por insuficiencia cardiaca: registro TRI-SPA","authors":"Julio Echarte-Morales ,&nbsp;Laura Sanchis ,&nbsp;Dabit Arzamendi ,&nbsp;Vanessa Moñivas ,&nbsp;Fernando Carrasco-Chinchilla ,&nbsp;Manuel Pan ,&nbsp;Luis Nombela-Franco ,&nbsp;Isaac Pascual ,&nbsp;Tomás Benito-González ,&nbsp;Ruth Pérez ,&nbsp;Iván Gómez-Blázquez ,&nbsp;Ignacio J. Amat-Santos ,&nbsp;Ignacio Cruz-González ,&nbsp;Ángel Sánchez-Recalde ,&nbsp;Ana Belén Cid Álvarez ,&nbsp;Manuel Barreiro-Pérez ,&nbsp;Pedro Cepas-Guillén ,&nbsp;Chi Hion Li ,&nbsp;María del Trigo ,&nbsp;José David Martínez-Carmona ,&nbsp;Rodrigo Estévez-Loureiro","doi":"10.1016/j.recesp.2025.02.002","DOIUrl":"10.1016/j.recesp.2025.02.002","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The prognostic impact of a history of heart failure hospitalizations (HFH) in patients undergoing transcatheter tricuspid edge-to-edge repair (T-TEER) has been scarcely studied. This study presents the results of the TRI-SPA registry, which includes data from 15 Spanish centers.</div></div><div><h3>Methods</h3><div>A multicenter, retrospective registry was conducted, including patients who underwent T-TEER between June 2020 and May 2023. Patients were classified into the 3 groups, based on the number of HFH in the 12 months prior to the procedure: no HFH, 1 HFH, and &gt;<!--> <!-->1 HFH (recurrent). The primary endpoint was all-cause mortality and HFH.</div></div><div><h3>Results</h3><div>Of the 262 patients included, 167 (63.7%) had no history of HFH, 60 (22.9%) had 1 HFH, and 35 (13.4%) had &gt;<!--> <!-->1 HFH. Patients with &gt;<!--> <!-->1 hospitalization had more comorbidities, higher surgical risk, and worse functional class; however, no significant differences were observed in the severity of tricuspid regurgitation either at baseline or after T-TEER. After a median follow-up of 365 [160-643] days, patients with recurrent HFH had higher rates of the composite outcome (9.9%, 16.7%, and 43.1%, respectively; <em>P<!--> </em>&lt;<!--> <!-->.001), as well as higher mortality rates (<em>P</em> <!-->=<!--> <!-->.036) and HFH (<em>P</em> <!-->&lt;<!--> <!-->.001). The number of HFH significantly decreased in the 12 months following T-TEER compared with the 12 months prior (<em>P</em> <!-->=<!--> <!-->.001).</div></div><div><h3>Conclusions</h3><div>Recurrent HFH within the 12 months prior to the procedure was associated with a higher risk of adverse clinical events during follow-up. T-TEER significantly reduced the number of hospitalizations during the follow-up period.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 9","pages":"Pages 800-810"},"PeriodicalIF":5.9,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144895210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comentarios a la guía ESC 2024 sobre el diagnóstico y tratamiento de la fibrilación auricular","authors":"Grupo de Trabajo de la SEC para la guía ESC 2024 sobre el diagnóstico y tratamiento de la fibrilación auricular y Comité de Guías de la SEC","doi":"10.1016/j.recesp.2024.10.011","DOIUrl":"10.1016/j.recesp.2024.10.011","url":null,"abstract":"","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 4","pages":"Pages 291-295"},"PeriodicalIF":5.9,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143706254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impacto de la calcificación valvular aórtica en el TAVI. ¿Debemos dar la vuelta a los conceptos previos?","authors":"Alberto Alperi ,&nbsp;Raquel del Valle ,&nbsp;Pablo Avanzas","doi":"10.1016/j.recesp.2024.12.009","DOIUrl":"10.1016/j.recesp.2024.12.009","url":null,"abstract":"","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 6","pages":"Pages 519-520"},"PeriodicalIF":5.9,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144134693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acetazolamida intravenosa en pacientes con insuficiencia cardiaca aguda y congestión persistente","authors":"Noelia Fernández Villa ,&nbsp;Sergio Manzano Fernández ,&nbsp;Miriam Gómez Molina ,&nbsp;Iris Paula Garrido Bravo ,&nbsp;Domingo Andrés Pascual Figal ,&nbsp;Francisco José Pastor Pérez","doi":"10.1016/j.recesp.2025.01.002","DOIUrl":"10.1016/j.recesp.2025.01.002","url":null,"abstract":"","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 8","pages":"Pages 736-738"},"PeriodicalIF":5.9,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144714371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shock cardiogénico en el infarto agudo de miocardio con enfermedad multivaso: estrategia de revascularización según el territorio isquémico","authors":"Ki Hong Choi ,&nbsp;Sang Yoon Lee ,&nbsp;Taek Kyu Park ,&nbsp;Joo Myung Lee ,&nbsp;Young Bin Song ,&nbsp;Joo-Yong Hahn ,&nbsp;Seung-Hyuk Choi ,&nbsp;Chul-Min Ahn ,&nbsp;Cheol Woong Yu ,&nbsp;Ik Hyun Park ,&nbsp;Woo Jin Jang ,&nbsp;Hyun-Joong Kim ,&nbsp;Jang-Whan Bae ,&nbsp;Sung Uk Kwon ,&nbsp;Hyun-Jong Lee ,&nbsp;Wang Soo Lee ,&nbsp;Jin-Ok Jeong ,&nbsp;Sang-Don Park ,&nbsp;Tae-Soo Kang ,&nbsp;Hyeon-Cheol Gwon ,&nbsp;Jeong Hoon Yang","doi":"10.1016/j.recesp.2024.05.010","DOIUrl":"10.1016/j.recesp.2024.05.010","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The association of revascularization strategy with clinical outcomes according to the ischemic territory of nonculprit lesion has not been documented in patients with acute myocardial infarction complicated by cardiogenic shock (AMI-CS). This study aimed to compare outcomes between culprit-only and immediate multivessel percutaneous coronary intervention (PCI) according to ischemic territory in patients with AMI-CS.</div></div><div><h3>Methods</h3><div>A total of 536 patients with AMI-CS and multivessel disease from the SMART-RESCUE registry were categorized according to ischemic territory (nonculprit left main/proximal left anterior descending artery [LM/pLAD] vs culprit LM/pLAD vs no LM/pLAD). The primary outcome was a patient-oriented composite endpoint (POCE) consisting of all-cause death, myocardial infarction, rehospitalization due to heart failure, or repeat revascularization at 1 year.</div></div><div><h3>Results</h3><div>Among the total population, 108 patients had nonculprit LM/pLAD, 228 patients had culprit LM/pLAD, and 200 patients had no LM/pLAD, with the risk of POCE being higher in patients with large ischemic territory lesions (53.6% vs 53.4% vs 39.6%; <em>P</em> = .02). Multivessel PCI was associated with a significantly lower risk of POCE compared with culprit-only PCI in patients with nonculprit LM/pLAD (40.7% vs 66.9%; HR, 0.52; 95%<span>C</span>I, 0.29-0.91; <em>P<!--> </em>=<!--> <!-->.02), but not in those with culprit LM/pLAD (<em>P<!--> </em>=<!--> <!-->.46) or no LM/pLAD (<em>P<!--> </em>=<!--> <!-->.47). A significant interaction existed between revascularization strategy and large nonculprit ischemic territory (<em>P<!--> </em>=<!--> <!-->.03).</div></div><div><h3>Conclusions</h3><div>Large ischemic territory involvement was associated with worse clinical outcomes in patients with AMI-CS and multivessel disease. Immediate multivessel PCI might improve clinical outcomes in patients with a large nonculprit ischemic burden.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 2","pages":"Pages 97-106"},"PeriodicalIF":5.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141844464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ejection fraction","authors":"Fernando A. Navarro","doi":"10.1016/j.recesp.2024.08.009","DOIUrl":"10.1016/j.recesp.2024.08.009","url":null,"abstract":"","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 2","pages":"Page 77"},"PeriodicalIF":5.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143211096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NT-proBNP en el ventrículo derecho sistémico, ¿un nuevo valor de corte para la estratificación del riesgo?","authors":"Fabian Tran ,&nbsp;Francisco Javier Ruperti-Repilado ,&nbsp;Philip Haaf ,&nbsp;Pedro Lopez-Ayala ,&nbsp;Matthias Greutmann ,&nbsp;Markus Schwerzmann ,&nbsp;Judith Bouchardy ,&nbsp;Harald Gabriel ,&nbsp;Dominik Stambach ,&nbsp;Juerg Schwitter ,&nbsp;Kerstin Wustmann ,&nbsp;Michael Freese ,&nbsp;Christian Mueller ,&nbsp;Daniel Tobler","doi":"10.1016/j.recesp.2024.05.013","DOIUrl":"10.1016/j.recesp.2024.05.013","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The role of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in the risk prediction of patients with systemic right ventricles (sRV) is not well defined. The aim of this study was to analyze the prognostic value of NT-proBNP in patients with an sRV.</div></div><div><h3>Methods</h3><div>The prognostic value of NT-proBNP was assessed in 98 patients from the SERVE trial. We used an adjusted Cox proportional hazards model, survival analysis, and c-statistics. The composite primary outcome was the occurrence of clinically relevant arrhythmia, heart failure, or death. Correlations between baseline NT-proBNP values and biventricular volumes and function were assessed by adjusted linear regression models.</div></div><div><h3>Results</h3><div>The median age [interquartile range] at baseline was 39 [32-48] years and 32% were women. The median NT-proBNP was 238 [137-429] ng/L. Baseline NT-proBNP concentrations were significantly higher among the 20 (20%) patients developing the combined primary outcome compared with those who did not (816 [194-1094] vs 205 [122-357]; <em>P</em> <!-->=<!--> <!-->.003). In patients with NT-proBNP concentrations<!--> <!-->&gt; 75th percentile (&gt; 429 ng/L), we found an exponential increase in the sex- and age-adjusted hazard ratio for the primary outcome. The prognostic value of NT-proBNP was comparable to right ventricular ejection fraction and peak oxygen uptake on exercise testing (c-statistic: 0.71, 0.72, and 0.71, respectively).</div></div><div><h3>Conclusions</h3><div>In patients with sRVs, NT-proBNP concentrations correlate with sRV volumes and function and may serve as a simple tool for predicting adverse outcomes.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 2","pages":"Pages 107-116"},"PeriodicalIF":5.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141852932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tiempos para la revascularización multivaso en pacientes estables con IAMCEST: revisión sistemática y metanálisis en red","authors":"Felix Voll ,&nbsp;Constantin Kuna ,&nbsp;Maria Scalamogna ,&nbsp;Thorsten Kessler ,&nbsp;Sebastian Kufner ,&nbsp;Tobias Rheude ,&nbsp;Hendrik B. Sager ,&nbsp;Erion Xhepa ,&nbsp;Jens Wiebe ,&nbsp;Michael Joner ,&nbsp;Robert A. Byrne ,&nbsp;Heribert Schunkert ,&nbsp;Gjin Ndrepepa ,&nbsp;Barbara E. Stähli ,&nbsp;Adnan Kastrati ,&nbsp;Salvatore Cassese","doi":"10.1016/j.recesp.2024.06.002","DOIUrl":"10.1016/j.recesp.2024.06.002","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>Multivessel percutaneous coronary intervention (MV-PCI) is recommended in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary artery disease (CAD) without cardiogenic shock. The present network meta-analysis investigated the optimal timing of MV-PCI in this context.</div></div><div><h3>Methods</h3><div>We pooled the aggregated data from randomized trials investigating stable STEMI patients with multivessel CAD treated with a strategy of either MV-PCI or culprit vessel-only PCI. The primary outcome was all-cause death. The main secondary outcomes were cardiovascular death, myocardial infarction, and unplanned ischemia-driven revascularization.</div></div><div><h3>Results</h3><div>Among 11 trials, a total of 10 507 patients were randomly assigned to MV-PCI (same sitting, n<!--> <!-->=<!--> <!-->1683; staged during the index hospitalization, n<!--> <!-->=<!--> <!-->3460; staged during a subsequent hospitalization within 45 days, n<!--> <!-->=<!--> <!-->3275) or to culprit vessel-only PCI (n<!--> <!-->=<!--> <!-->2089). The median follow-up was 18.6 months. In comparison with culprit vessel-only PCI, MV-PCI staged during the index hospitalization significantly reduced all-cause death (risk ratio, 0.73; 95%<span>C</span>I, 0.56-0.92; <em>P</em> <!-->=<!--> <!-->.008) and ranked as possibly the best treatment option for this outcome compared with all other strategies. In comparison with culprit vessel-only PCI, a MV-PCI reduced cardiovascular mortality without differences dependent on the timing of revascularization. MV-PCI within the index hospitalization, either in a single procedure or staged, significantly reduced myocardial infarction and unplanned ischemia-driven revascularization, with no significant difference between each other.</div></div><div><h3>Conclusions</h3><div>In patients with STEMI and multivessel CAD without cardiogenic shock, multivessel PCI within the index hospitalization, either in a single procedure or staged, represents the safest and most efficacious approach. The different timings of multivessel PCI did not result in any significant differences in all-cause death.</div><div>This study is registered at PROSPERO (CRD42023457794).</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 2","pages":"Pages 127-137"},"PeriodicalIF":5.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143211144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Riesgo de eventos cardiovasculares graves tras agudizaciones de la EPOC: resultados del estudio EXACOS-CV en España","authors":"Salud Santos ,&nbsp;Nicolás Manito ,&nbsp;Joaquín Sánchez-Covisa ,&nbsp;Ignacio Hernández ,&nbsp;Carmen Corregidor ,&nbsp;Luciano Escudero ,&nbsp;Kirsty Rhodes ,&nbsp;Clementine Nordon","doi":"10.1016/j.recesp.2024.06.004","DOIUrl":"10.1016/j.recesp.2024.06.004","url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>This real-world study—the first of its kind in a Spanish population—aimed to explore severe risk for cardiovascular events and all-cause death following exacerbations in a large cohort of patients with chronic obstructive pulmonary disease (COPD).</div></div><div><h3>Methods</h3><div>We included individuals with a COPD diagnosis code between 2014 and 2018 from the BIG-PAC health care claims database. The primary outcome was a composite of a first severe cardiovascular event (acute coronary syndrome, heart failure decompensation, cerebral ischemia, arrhythmia) or all-cause death following inclusion in the cohort. Time-dependent Cox proportional hazards models estimated HRs for associations between exposed time periods (1-7, 8-14, 15-30, 31-180, 181-365, and &gt;<!--> <!-->365 days) following an exacerbation of any severity, and following moderate or severe exacerbations separately (vs unexposed time before a first exacerbation following cohort inclusion).</div></div><div><h3>Results</h3><div>During a median follow-up of 3.03 years, 18 901 of 24 393 patients (77.5%) experienced ≥ 1 moderate/severe exacerbation, and 8741 (35.8%) experienced the primary outcome. The risk of a severe cardiovascular event increased following moderate/severe COPD exacerbation onset vs the unexposed period, with rates being most increased during the first 1 to 7 days following exacerbation onset (HR, 10.10; 95%CI, 9.29-10.97) and remaining increased &gt;<!--> <!-->365 days after exacerbation onset (HR, 1.65; 95%CI, 1.49-1.82).</div></div><div><h3>Conclusions</h3><div>The risk of severe cardiovascular events or death increased following moderate/severe exacerbation onset, illustrating the need for proactive multidisciplinary care of patients with COPD to prevent exacerbations and address other cardiovascular risk factors.</div></div>","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 2","pages":"Pages 138-150"},"PeriodicalIF":5.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143211116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sistema de reparación mitral DragonFly: primera experiencia en España","authors":"Claudio E. Guerreiro ,&nbsp;Rodrigo Estévez-Loureiro ,&nbsp;Manuel Barreiro-Pérez ,&nbsp;Rocío González-Ferreiro ,&nbsp;José A. Baz ,&nbsp;Andrés Íñiguez-Romo","doi":"10.1016/j.recesp.2024.07.012","DOIUrl":"10.1016/j.recesp.2024.07.012","url":null,"abstract":"","PeriodicalId":21299,"journal":{"name":"Revista espanola de cardiologia","volume":"78 2","pages":"Pages 151-153"},"PeriodicalIF":5.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143211117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}